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Abstract: Recently, genetic alterations in the genes encoding succinate dehydrogenase subunit B
and D (SDHB and SDHD) were identified in pet dogs that presented with spontaneously arising
pheochromocytomas (PCC) and paragangliomas (PGL; together PPGL), suggesting dogs might be an
interesting comparative model for the study of human PPGL. To study whether canine PPGL resembled
human PPGL, we investigated a series of 50 canine PPGLs by immunohistochemistry to determine the
expression of synaptophysin (SYP), tyrosine hydroxylase (TH) and succinate dehydrogenase subunit
A (SDHA) and B (SDHB). In parallel, 25 canine PPGLs were screened for mutations in SDHB and
SDHD by Sanger sequencing. To detect large chromosomal alterations, single nucleotide polymorphism
(SNP) arrays were performed for 11 PPGLs, including cases for which fresh frozen tissue was available.
The immunohistochemical markers stained positive in the majority of canine PPGLs. Genetic screening of
the canine tumors revealed the previously described variants in four cases; SDHB p.Arg38Gln (n = 1) and
SDHD p.Lys122Arg (n = 3). Furthermore, the SNP arrays revealed large chromosomal alterations of which
the loss of chromosome 5, partly homologous to human chromosome 1p and chromosome 11, was the most
frequent finding (100% of the six cases with chromosomal alterations). In conclusion, canine and human
PPGLs show similar genomic alterations, suggestive of common interspecies PPGL-related pathways.
Keywords: dog; pheochromocytoma; paraganglioma; SDHB; SDHD; mutation; chromosomal
alteration; comparative genomics
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1. Introduction
Pheochromocytomas (PCCs) and paragangliomas (PGLs; together PPGLs) are tumors arising from
chromaffin tissue inside (PCC) and outside the adrenal glands (PGL). These tumors occur in the context
of several hereditary syndromes, such as Von Hippel Lindau (VHL), Multiple Endocrine Neoplasia type
2, Neurofibromatosis type 1, and the PCC-PGL syndrome, with underlying germline mutations in the
VHL, rearranged during transfection (RET), neurofibromin 1 (NF1), and the SDH-genes, respectively [1].
Both germline and somatic mutations can be found in more than 20 genes [2,3]. Although approximately
10% of PPGL patients, in general, will present with (distant) metastases, this frequency is much higher
in patients with succinate dehydrogenase subunit B (SDHB) germline mutations. During follow-up,
more than 35% of SDHB patients will present with PPGL metastases [4,5].
In an effort to unravel the mechanisms behind malignant behavior of PPGLs, and more specifically
the metastatic behavior of SDHB-related tumors, several attempts have been made to generate knock-out
mouse models. These models either proved lethal during embryogenesis or the mice did not develop
PPGL or other SDH-related tumors [6]. The only mouse models that presented with high frequencies
of PCCs were based on conditional homozygous inactivation of Pten and heterozygous conventional
inactivation of Nf1 [7]. However, human PPGLs have never been associated with phosphatase and
tensin homolog (PTEN) mutations [8]. In addition, NF1-related PPGLs are relatively benign with
metastatic behavior seen in fewer than 10% of cases [9]. So, although these PPGL mouse models are
interesting, there remains a need for an appropriate animal model to study SDH-related PPGL.
Recently, Holt et al. reported genetic screening of eight canine PPGLs and identified four genetic
variants that might be potentially pathogenic; one in SDHB (p.Arg38Gln) and three in succinate
dehydrogenase subunit D (SDHD; p.Lys122Arg), of which one was somatic [10]. Because these
alterations occurred in highly conserved amino acids, the authors assumed that the alterations were
likely pathogenic. In fact, the somatic event suggests that at least the SDHD p.Lys122Arg amino acid
change is likely pathogenic, while the SDHB alteration remains of unknown significance. Since this is
the first animal model that presents spontaneously with PPGL that might be related to SDHB and SDHD
mutations, we have investigated a relatively large series of canine PPGLs by Sanger sequencing for
mutations in these genes. In addition, immunohistochemistry was performed for tyrosine hydroxylase,
synaptophysin, SDHB, and succinate dehydrogenase subunit A (SDHA), and SNP arrays to identify
chromosomal alterations.
2. Results
2.1. Clinical Findings
The canine PPGL immunohistochemistry series included 32 PCCs and 18 PGLs. The average age of
the dogs at diagnosis was 11 years for PCCs (ranging from 4 to 16 years) and 9 years for PGLs (ranging
from 2 to 11 years). In the PCC group, the distribution of males and females was almost identical
(53% male), while the PGL group included more tumors from males (72%). Metastatic behavior was
reported in 3% of the dogs with PCCs (n = 1) and 11% of the dogs with PGL (n = 2).
2.2. Genetic Analyses
Sanger sequencing results are shown in Table 1. Twenty-one PPGLs (20 PCCs and one
PGL) with sufficient DNA quality and positive synaptophysin (SYP) or tyrosine hydroxylase (TH)
immunohistochemical labeling, were screened for mutations in the SDHB and SDHD genes. If a tumor
had a non-synonymous variant, the presence of this variant was also investigated in corresponding
germline DNA.
Three PCCs showed an SDHD (XM_536573) c.365A>G; p.Lys122Arg alteration. In PCC6 and
PCC46 the variant was homozygous, while in PCC23 the alteration was heterozygous. Germline DNA
was only available for PCC6 and showed the SDHD variant in a heterozygous fashion, indicating loss
of the wild type (WT) SDHD allele in the tumor (Figure 2), which was also confirmed by the loss of
Cancers 2019, 11, 607 3 of 11
heterozygosity analyses for microsatellite markers flanking the SDHD gene (Figure 1B). PCC19 showed
the previously described SDHB (NM_001252217) c.113G>A; p.Arg38Gln alteration, which appeared
homozygous in the tumor and corresponding germline DNA of this dog. (Figure 1A)
In addition, genetic screening for SDHA mutations was only performed in SDHA
immunohistochemically-negative tumor PCC1 (see below Figure 2). Due to the relatively poor
quality of the sample it was not possible to obtain SDHA DNA sequences of sufficient quality
to analyze.
2.3. Immunohistochemistry
SYP was positive in 86% of PCCs and 71% of PGLs, while TH was positive in 74% of PCCs
and 35% of PGLs. Results of the immunohistochemistry of all tumors are listed in Supplemental
Table S1 and illustrated in Figure 1. SDHB immunohistochemistry was performed on all 50 canine
PPGLs. PCC1 and PCC6 showed heterogeneous labeling for SDHB, with foci of tumor cells that were
immunohistochemically negative for SDHB and areas that were weakly positive. The SDHA labeling
for PCC1 also appeared to be negative for the tumor cells in this PCC (Figure 2), while all other tumors
were positive. All other PPGLs, as well as the positive control tissues (normal dog adrenals), were
immunohistochemically positive, although they did not show the typical granular labeling pattern.
2.4. SNP Arrays
Chromosomal alterations were investigated for 11 dog PPGLs by SNP arrays. From those, analysis
was not possible for two samples due to high background noise. In addition, three tumors did not
show any chromosomal alterations. The chromosomal alterations of the six remaining tumors are
listed in Table 2. Furthermore, an illustrative single nucleotide polymorphism (SNP) array result of
case PCC20 (logR ratios and b-allele frequencies (BAF)) is depicted in Figure 1C, showing loss of
chromosomes 5, 17, 23, 26, 30, and 34. The most frequent genomic alteration was loss of chromosome 5,
which occurred in all six dog PPGLs (100%), followed by loss of chromosome 26 in 5/6 dog PPGLs
(83%). Chromosome 5 (CanFam3.1) is, for a large part, syntenic to two areas of human chromosome 1
(GRCh38.p3), and to a part of human chromosome 11, including the SDHD region, respectively (see
Figure 3, Supplemental Table S3). Genomic locations of SDHA, SDHB, SDHC, and SDHD are shown in
Supplemental Figure S2.
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Figure 1. (A) In the left panel, succinate dehydrogenase subunit B (SDHB) sequences are displayed from
healthy reference (upper), PCC19, and corresponding germline DNA. In the right panel, the succinate
dehydrogenase subunit D (SDHD) sequence is shown from healthy reference, PCC6, and corresponding
germline DNA. Note that PCC19 tumor and germline DNA both show the SDHB c.113G>A; p.Arg38Gln
variant. PCC6 shows SDHD c.365A>G; p.Lys38Arg in a homozygous fashion in the tumor DNA and
heterozygous in the germline DNA, indicating loss of the wild type allele in the tumor. (B) Shows loss
of heterozygosity of the larger allele in PCC6, confirming the Sanger sequencing results. (C) The SNP
array result of PCC 20 displays in the upper panel logR ratios, indicating loss of chromosomes 5, 17, 23,
26, 30, and 34. This is also seen in the lower panel by the B-allele frequencies.
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Figure 2. Hematoxylin Eosin staining and immunohistochemistry for synaptophysin (SYP), tyrosine
hydroxylase (TH), succinate dehydrogenase subunit A (SDHA) and subunit B (SDHB) of normal dog
adrenal, PCC1, and PCC6. Normal adrenal glands were used as positive controls and show strong
expression of SYP and tyrosine hydroxylase (TH). PCC1 and 6 label weakly positive for SYP, but for
TH only PCC1 shows positive labeling. The normal canine adrenal gland labels positive for SDHA
and SDHB, although there is lack of granular labeling, which is characteristic for SDHA and SDHB in
human tissues. PCC1 shows labeling of the stromal cells for SDHA and SDHB, which serve as positive
control cells, while the PCC cells appear to be heterogeneous weak/negative for SDHB and do not label
for SDHA. PCC 6 showed heterogeneous weak expression of SDHB, but there was no difference in
labeling intensity between the tumor cells and the normal stromal cells for SDHA. Pictures are at 20×
magnification, internal boxes at 40× magnification.
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Figure 3. Homology between dog chromosome 5 and 26, and the human genome. It shows the
homology between dog chromosome 5 and 26 and several human chromosomes. Of note is that the
SDHD gene is located on dog chromosome 5 (see Supplemental Figure S2).
Table 1. Variants identified by Sanger Sequencing. SDH-variants that were previously described by
Holt et al. [10] as mutations are depicted in bold and italic. If a non-synonymous variation was detected
in the tumor, the corresponding germline was investigated for the presence of the variant.
PCC Number SDHB Synonymous SDHBNon-Syn SDHD Syn
SDHD
Non-Syn Comment
PCC1 p.Y50Y, p.Q164Q, p.A210A WT
PCC2 p.Y150Y, p.Q164Q, p.A210A WT
PCC3 WT WT
PCC4 p.A210A WT
PCC5 p.Y150Y, p.Q164Q, p.L188L, p.A210A WT
PCC6 p.Y150Y, p.Q164Q, p.A210A p.A97A p.K122RHO/HE LOH confirmed
PCC9 p.Y150Y, p.Q164Q, p.A210A WT
PCC10 p.Y150Y, p.Q164Q, p.A210A WT
PCC11 p.L188L WT
PCC13 p.L188L WT
PCC14 p.L188L WT
PCC15 p.Y150Y, p.Q164Q, p.L188L, p.A210A WT
PCC16 p.L188L WT
PCC17 WT WT
PCC18 p.L188L WT
PCC19 p.Y150Y, p.Q164Q, p.A210A p.R38QHO/HO WT loss Chr. 5
PCC20 p.L188L WT loss Chr. 5
PCC21 p.Y150Y, p.Q164Q, p.L188L, p.A210A WT
PCC22 p.Y150Y, p.Q164Q, p.L188L, p.A210A WT
PCC23 p.Y150Y, p.Q164Q, p.L188L, p.A210A p.A97A p.K122RHE
PCC46 NA WT p.K122RHO loss Chr.5
HO = homozygous in tumor (PCC46); HE = heterozygous in tumor (PCC23); HO/HE = homozygous in variant
in tumor, heterogeneous in germline; HO/HO = homozygous variant in both tumor and germline; LOH = loss
of heterozygosity in tumor, loss of chromosome 5 detected with the SNP array are indicated in the comments,
non-syn = non-synonymous, syn = synonymous.
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Table 2. Summary of single nucleotide polymorphism (SNP) array results.
Chromosome PCC19 PCC20 PCC36 * PCC37 * PCC43 * PCC46 *
2 LOSS
3 LOSS
5 LOSS LOSS LOSS LOSS LOSS LOSS
7 LOSS LOSS LOSS
8 LOSS
9 GAIN
12 LOSS
15 LOSS
16 LOSS LOSS
17 LOSS LOSS
18 LOSS
20 LOSS LOSS
21 LOSS
22 LOSS
23 LOSS
25 LOSS
26 LOSS LOSS LOSS LOSS LOSS
27
28
29 LOSS
30 LOSS LOSS
31 LOSS LOSS
32 LOSS LOSS LOSS
34 LOSS LOSS
35 LOSS LOSS
Overview of large chromosomal changes in the informative dog PPGL. * Noisy sample.
3. Discussion
Currently, there is still no curative therapy for patients with metastatic PPGL. In general, malignant
behavior occurs in 10% of patients with PPGL. However, patients with SDHB germline mutations have
a much higher chance of developing distant metastases [11]. Investigating animal models of PPGL
could lead to the development and testing of therapies for humans with metastatic PPGL. Thus far,
the only animal model that presents with metastatic PCC is a Pten KO mouse [12,13]. Since PTEN
mutations do not play a role in the pathogenesis of human (malignant) PPGL, such models are not the
most suitable for the study of human malignant PPGL [8]. A recent study reported that dogs presenting
spontaneously with PPGL had potential pathogenic genetic alterations in SDHB and SDHD [10].
To investigate these results in an independent and larger series we have screened 25 canine PPGLs for
mutations and identified one SDHB and three non-synonymous SDHD genetic alterations, both of
which have been described previously [10].
The SDHD p.Lys122Arg variant was identified in three canine PPGLs; once in a heterozygous
(PCC23) and twice in a homozygous fashion (PCC6 and PCC46). The corresponding germline DNA
from PCC6 showed the variant to be present in a heterozygous fashion, indicating loss of the wild
type SDHD allele in the tumor DNA. This finding was confirmed by the loss of heterozygosity (LOH)
analysis, using microsatellites flanking the SDHD gene. Although there was no germline DNA available
for PCC46, the homozygous expression of the SDHD p.Lys122Arg variant in the tumor could be
explained by the potential loss of the SDHD wild type, since the SNP array results showed loss of
chromosome 5, which includes the SDHD gene. However, this is only speculation, since we cannot
confirm the possibility that the SDHD variant was heterozygous in the germline DNA, and could also
be present as a homozygous SDHD p.Lys122Arg or homozygous wild type.
In addition, another previously described non-synonymous SDHB variant [10] was detected in
PCC19. This tumor showed the SDHB p.Arg38Gln variant in a homozygous fashion, which was also
homozygous in DNA isolated from normal tissue from the same dog. Although the SDHB p.Arg38 is a
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highly conserved amino acid throughout many species, the fruit fly has a Gln at position 38. Since the
variant was already present in a homozygous fashion in the germline, no loss of the SDHB locus was
seen in the SNP array results. As the p.Arg38Gln amino acid change is probably not deleterious to
the function of the protein, we regard this variant as likely benign. However, this should be further
investigated functionally.
Sanger sequencing screening of this tumor did not reveal any novel mutations in SDHB and SDHD.
However, mutations could have been missed due to the poor DNA quality, resulting in sequences that
could not be analyzed, and due to other driving mechanisms, such as promoter-methylation or large
(exon) deletions, which are not detectable by Sanger sequencing [14–16].
The SDHA and SDHB immunohistochemistry appeared to be positive in almost all investigated
tumors, with the exception of PCC1 and PCC6. PCC1 also was immunohistochemically negative for
SDHA. However, since the positive control tissues (normal dog adrenals) showed homogeneous and
not granular cytoplasmic labeling, we suspect that the antibody is not suitable for screening for SDH
mutations, as in human PPGL [17,18], and, therefore, no conclusions can be drawn from the SDHA
and SDHB immunohistochemistry. In addition, the negative/weak positive SDHA and SDHB labeling
could also be due to technical limitations, such as fixation artifacts.
The SNP array results showed large chromosomal alterations in six of the nine PPGLs with
informative SNP arrays. The fact that three tumors did not show chromosomal aberrations was most
likely due to the low neoplastic cell content of these frozen tissue samples, from which DNA was
isolated. From the six tumors that showed chromosomal alterations, loss of chromosome 5 was the
most frequent alteration (100%). Canine chromosome 5 shows homology with regions of human
chromosome 1p and 11q. Many studies have shown that loss of chromosome 1p and chromosome
11 are frequent events in the pathogenesis of human PPGL [3,19,20]. Our results suggest that there
are common genes, located in these homologous chromosomal areas, that might contribute to the
pathogenesis of both human and canine PPGL.
4. Materials and Methods
4.1. Patients and Sample Selection
In total, we collected 50 dog PPGLs from 45 dogs (including one case with bilateral tumors), which
comprised of 44 formalin-fixed paraffin wax-embedded (FFPE) blocks and six fresh frozen samples
(FF), from contributing Veterinary faculties from the University of Bristol, Bristol, United Kingdom (n
= 25), Utrecht University, Utrecht, the Netherlands (n = 12), University of Zurich, Zurich, Switzerland
(n = 8), and University of Bologna, Bologna, Italy (n = 5). In addition, we also collected three normal
canine adrenal glands provided by the Veterinary Faculty of Utrecht University, to be used as positive
controls for the immunohistochemistry. In addition, from two dogs, corresponding germline DNA
was available (PCC6 and PCC19). All tissue samples were collected during surgery or necropsy
examination from pet dogs suffering from PPGL. The owners of the dogs had given permission for the
tissues to be used for research purposes. All clinical characteristics including age, breed, and gender
are listed in Supplemental Table S1. PPGLs were only considered malignant if distant metastases were
present, as for human PPGL. A summary of the current study is shown in Supplemental Figure S1.
4.2. Immunohistochemistry
Immunohistochemistry was performed for all canine samples to confirm the diagnosis of PPGL
using markers for synaptophysin (SYP) and tyrosine hydroxylase (TH). SYP and TH were evaluated
by Esther Korpershoek and Daphne Dieduksman and scored as positive if there was a weak to
strong specific expression in the cytoplasm of all tumor cells. SYP was labeled using the Ventana
Benchmark ULTRA automated immunohistochemistry stainer (details available on request), while TH
immunohistochemistry was performed as previously described [13]. Since in human PPGL, negative
SDHB immunohistochemistry reliably identifies tumors with mutations in SDHA, SDHB, SDHC,
Cancers 2019, 11, 607 9 of 11
or SDHD, we also investigated the immunohistochemical expression of SDHB in the canine PPGLs [21].
The peptide to which this SDHB antibody was generated is 99% homologous to the canine peptide;
only one of 108 amino acid residues is different. The series of canine PPGLs was also labeled for
SDHA, as described previously [17]. Normal dog adrenal glands were used as positive controls
for immunohistochemistry. The immunohistochemistry was performed on 5 µm sections using the
Ventana automated stainer as described previously [18]. SDHB and SDHA expression was scored as
positive if strong expression was observed in all cells, while a tumor was considered as negative if
the labeling of the tumor cells was negative or weakly positive compared with the positive granular
labeling present in the surrounding endothelial cells, which serve as internal positive controls [17,21].
4.3. Genetic Screening
In total, 24 PPGLs (Supplemental Table S1) that expressed SYP and/or TH immunohistochemically
were selected for the genetic screening and one TH/SYP negative PCC was also studied. For the FFPE
samples, DNA isolation was performed by manual microdissection, to ensure that the DNA was derived
from a high percentage of neoplastic cells. DNA isolation was performed with the DNaesy kit (#69504,
Qiagen, Venlo, the Netherlands) according to the manufacturer’s protocol. DNA concentrations
were measured with the Qubit®dsDNA HS BR assay kit (#Q32850, Thermo Fisher, Waltham, MA,
USA) according to the manufacturer’s instructions. For the generation of the primers, human SDHA
(NM_004168), SDHB (NM_003000), and SDHD (MN_003002) mRNA sequences were aligned with
the dog genome (CanFam3.1/canFam3) to identify the exact location and sequences of the genes and
exons, enabling the generation of dog-specific primers covering all of the coding sequences. PCR was
performed with KAPA2G Hotstart Readymix (#KK5004, Sopachem, Ochten, the Netherlands) for
which conditions were optimized per primer pair and are listed, together with the primer sequences,
in Supplemental Table S2. In total, 21 DNA samples were of sufficient quality to be screened for
mutations. Due to technical limitations, we were unable to investigate exon 1 and 8 of SDHB, and exon
1 and 2 of SDHD. Sanger sequencing was performed as previously described [17].
4.4. Loss of Heterozygosity
To confirm the loss of the wild type allele in SDHD-mutated samples, LOH analysis was
performed using two microsatellite markers located upstream and downstream from the dog SDHD
gene. Primer sequences and PCR conditions are indicated in Supplemental Table S2. Furthermore, PCR
was performed as previously described [17].
4.5. SNP Arrays:
To determine the chromosomal alterations present in dog PCC, we performed SNP arrays on
11 canine PPGLs (Table 2). Canine HD Beadchip SNP arrays (#WG-440-1001, Illumina, San Diego,
CA, USA) with a high resolution genome-wide coverage (170,000 SNPs; resolution of approximately
15 SNPs per Mb) were performed and analyzed according to standard procedures at the Human
Genomics Facility (HuGeF), Erasmus MC, University Medical Center Rotterdam (www.glimdna.org).
Final report output files, containing B-allele frequencies and logR ratios, were generated using
Illumina BeadStudio Software. The processed files were accordingly visualized using Nexus Copy
Number software package (V7.5; Biodiscovery, El Segundo, CA, USA). The SNP array results were
submitted to the Gene Expression Omnibus Database. Noisy samples that clearly showed a drop or
gain in B-allele frequencies and logR of entire chromosomes were still included in the analysis, taking
into account the risk of missing subtle chromosomal changes.
5. Conclusions
In conclusion, the results of the current study indicate that similar genomic alterations occur in
canine and human PPGLs. Although more functional proof is required to classify the pathogenicity for
the SDHD p.Lys122Arg variant, our data suggest that this variant could potentially be pathogenic.
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Since chromosomal alterations occurred in the dog PPGL at high frequency, affecting chromosomes
that are homologous to regions that are also repeatedly lost in human PPGLs, we propose that canine
PPGLs are an interesting model for the study of the pathogenesis of human PPGL [22]. More studies
are required to identify which common pathways are involved in the pathogenesis of PPGL in both
humans and dogs.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/11/5/607/s1,
Figure S1: Summary of study design and results, Figure S2: Genomic locations SDH-related genes in the dog
genome according to NCBI Genome Data viewer. Table S1: Clinical data, immunohistochemistry results and
gene alterations in dog PPGL, Table S2: Primers, Table S3: Homology overview dog chromosome 5 and 26 with
human genome.
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